zeaxanthin dipalmitate

from fruit of Lycium chinense; structure in first source

Networked: 8 relevant articles (0 outcomes, 2 trials/studies)

1.	Alcoholic Fatty Liver 01/01/2014 - "Zeaxanthin dipalmitate therapeutically improves hepatic functions in an alcoholic fatty liver disease model through modulating MAPK pathway." 09/01/2017 - "Zeaxanthin dipalmitate alleviates hepatic injury induced by superimposed chronic hepatitis B and non-alcoholic steatohepatitis in non-obese mice." 01/01/2014 - "In the current study, the therapeutic effects of zeaxanthin dipalmitate (ZD) on a rat alcoholic fatty liver disease (AFLD) model were evaluated. "
2.	Acute Liver Failure (Fulminant Hepatic Failure) 01/01/2017 - "In the current study, we demonstrated that a small molecule zeaxanthin dipalmitate (ZD) could enhance the defensive abilities against adverse stresses of human adipose-derived mesenchymal stem cells (hADMSCs) in vitro and increase their therapeutic outcomes of acute liver failure after transplantation in vivo. "
3.	Chronic Hepatitis B 09/01/2017 - "Zeaxanthin dipalmitate alleviates hepatic injury induced by superimposed chronic hepatitis B and non-alcoholic steatohepatitis in non-obese mice."
4.	Retinitis Pigmentosa (Pigmentary Retinopathy) 01/01/2021 - "Wolfberry-derived zeaxanthin dipalmitate delays retinal degeneration in a mouse model of retinitis pigmentosa through modulating STAT3, CCL2 and MAPK pathways."
5.	Retinal Degeneration 01/01/2021 - "Wolfberry-derived zeaxanthin dipalmitate delays retinal degeneration in a mouse model of retinitis pigmentosa through modulating STAT3, CCL2 and MAPK pathways."

1.	Transplantation